·Ç°ÐÏò´úл×éѧ£¨Untargeted Metabolomics£©Ö÷Òª»ùÓÚLC-MS¡¢GC-MS¡¢NMRÊÖÒÕ£¬ÎÞÆ«ÏòÐԵأ¬¾¡¿ÉÄܶàµØ¼ì²âËùÓеÄС·Ö×Ó´úлÎ¶ÔÓлúÌåÔÚһ׼ʱ¼äºÍ¿Õ¼äϱí´ïµÄËùÓдúлÎï¾ÙÐж¨ÐÔ¶¨Á¿ÆÊÎö£¬ÊÇÑ°ÕÒ´úлÎïÓëÐÄÀí²¡Àíת±äÏà¶Ô¹ØϵµÄÑо¿·½·¨£¬ÆäÑо¿¹¤¾ß´ó¶¼ÊÇ·Ö×ÓÁ¿1500ÒÔÄÚµÄС·Ö×ÓÎïÖÊ¡£
±¾¹«Ë¾½ÓÄÉUHPLC-QTOF-MS£¨Agilent 1290 Infinity¢òUHPLC- AB SCIEX Triple TOF 6600 MS£©£¬UHPLC-QTOF-MS£¨Agilent 1290 Infinity ¢òUHPLC- Agilent 6545 MS£©¾ßÓиü¸ßÉ«Æ×ÊèÉ¢¶È£¬¾ßÓм«µÍµÄ¼ì²âÏ޺ͳ¬¿íµÄ¶¯Ì¬¹æÄ££»Agilent 6545¾ßÓиü¸ßµÄѸËٶȺ;«²ÊµÄÎȹÌÐÔ£¬¶þÕßÍŽá¿ÉÌṩ¸ü¸ßµÄÊèÉ¢ÄÜÁ¦ºÍѸËٶȣ¬ÓÃÓÚÉúÎïÑù±¾ÖÐÖØ´ó´úл²úÆ·¼ì²âºÍDZÔÚ±ê¼ÇÎïÅжϣ¬»ñµÃ¸ü׼ȷµÄÆÊÎöЧ¹û£¬ÒѼì²â³ö¶à´ï½üǧÖÖ´úлÎº¸ÇÎïÖÊÖÖÀ฻ºñ£¬Ñù±¾Ç°´¦Öóͷ£¼òÆÓ£¬³ÉÄÚÇé¶Ô½ÏµÍ£¬±¾¹«Ë¾½ÓÄɸßÇø·ÖÂÊ×Ô½¨¿â£¬DB_all¹«¹²¿â¡¢AIÕ¹Íû¿âÒÔ¼°MetDNA¹²¼Æ4ÖÖÒªÁì¾ÙÐÐÅжϣ¬Ò»´ÎÆÊÎö£¬½â¾öËùÓÐÎÊÌâ¡£
1.¸üÏȽøµÄƽ̨ѡÔñ
2.¸ü¸»ºñµÄÊÖÒÕʵÁ¦ºÍÂÄÀú
3.¸ü³ÉÊìµÄÊý¾ÝÆÊÎöÏ¢Õù¶ÁÄÜÁ¦-¾ß±¸ÓÅÒìµÄÉúÎïÐÅϢѧÍŶӣ¬Äܹ»ÌṩÖÜÈ«µÄÊý¾ÝÆÊÎöЧÀͺÍ׼ȷµÄЧ¹û½â¶Á
4.¸üÎÞаµÄ¶¨ÖÆ»¯ÆÊÎö¼Æ»®-¾ß±¸×¨ÒµµÄת»¯Ò½Ñ§ÍŶӣ¬Äܹ»ÊµÊ±¸ú½øÇ°ÑØÎÄÏ×£¬Ìṩ¸öÐÔ»¯µÄʵÑéÉè¼ÆºÍ¼Æ»®
5.¸üÓŻݵļÛÇ®ºÍ¸ü¶ÌµÄ½»¸¶ÖÜÆÚ-Ìṩ×ۺϱȼÛͨµÀ£¬²¢ÄܸßЧ¸ßÖÊÁ¿µÄ½»¸¶Ð§¹û
ҽѧÑо¿£º¼²²¡±ê¼ÇÎïɸ²é£»²¡ÒòÓ벡Àí»úÖÆ̽ÌÖ£»¼²²¡¸´·¢Õï¶Ï£»¼²²¡Õï¶ÏÓë·ÖÐÍ£»ÁÙ´²ÁÆЧÆÀ¼Û£»Ò©ÎﶾÀíѧÆÀ¼Û¡£
ÉúÃü¿ÆѧÑо¿£º·ÇÉúÎïÇéÐÎÑо¿£»´úл;¾¶¼°¹¦Ð§»ùÒò×éÑо¿£»Ö²ÎïÓë΢ÉúÎïÑо¿£»Ò©ÓÃÖ²ÎïÑо¿£»±íÐÍÅжÏÓ¦Óá£
ѪÇ塢Ѫ½¬£º200¦ÌL/sample
ÄòÒº£º1mL/sample
×éÖ¯£º200mg/sample
·à±ã¡¢³¦µÀÄÚÈÝÎ200mg/sample
ϸ°û¡¢Î¢ÉúÎ1¡Á107cells/sample
Ö²ÎïºÍ΢ÉúÎï¡Ý6
¶¯ÎïÑù±¾¡Ý10
ÁÙ´²Ñù±¾¡Ý30
Altered faecal microbiome and metabolome in IgG4-related sclerosing cholangitis and primary sclerosing cholangitis
±¾Ñо¿¶ÔÁÙ´²Ó²»¯ÐÔµ¨¹ÜÑ×£¨IgG4-SC£©ÓëÔ·¢ÐÔÓ²»¯ÐÔµ¨¹ÜÑ×£¨PSC£©»¼Õߵķà±ã£¬½ÓÄÉ16S rRNA¼°´úл×é¼ì²âÊֶΣ¬Í¨¹ý×ÛºÏÆÊÎöÈ·¶¨ÁËIgG4 SCºÍPSCÖвî±ðµÄËÞÖ÷-΢ÉúÎï¹ØÁªÐÔ£¬ÇÒ·¢Ã÷»ùÓÚ´úлÎïÕ¹ÍûÄ£×ӱȻùÓÚ΢ÉúÎïÕ¹ÍûÄ£×Ó¸üÄÜÓÐÓõØÇø·Ö¼²²¡×´Ì¬£¬Í¬Ê±Ñо¿Êý¾ÝÖ§³ÖIgG4-SCÆæÒìÐÔ¡£
Ñо¿Åú×¢£¬IgG4-SCºÍPSC¾ßÓвî±ðµÄËÞÖ÷-΢ÉúÎïÏ໥×÷Óã¬Õâ¿ÉÄÜÓë¼²²¡·¢²¡»úÖÆÓйء£±¾Ñо¿Êý¾ÝÇ¿µ÷ÁËIgG4-SCµÄÆæÒìÐÔ¡£